Matches in DBpedia 2016-04 for { ?s ?p "Ian Hector Frazer AC (born 6 January 1953) is a Scottish-born Australian scientist and founding CEO and Director of Research of the Translational Research Institute (Australia).Frazer and his colleagues developed and patented the basic technology behind the HPV vaccine against cervical cancer at The University of Queensland, now marketed as Gardasil and Cervarix; which was the second cancer preventing vaccine, and the first vaccine designed to prevent a cancer. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Ian_Frazer abstract "Ian Hector Frazer AC (born 6 January 1953) is a Scottish-born Australian scientist and founding CEO and Director of Research of the Translational Research Institute (Australia).Frazer and his colleagues developed and patented the basic technology behind the HPV vaccine against cervical cancer at The University of Queensland, now marketed as Gardasil and Cervarix; which was the second cancer preventing vaccine, and the first vaccine designed to prevent a cancer. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.".
- Q930011 abstract "Ian Hector Frazer AC (born 6 January 1953) is a Scottish-born Australian scientist and founding CEO and Director of Research of the Translational Research Institute (Australia).Frazer and his colleagues developed and patented the basic technology behind the HPV vaccine against cervical cancer at The University of Queensland, now marketed as Gardasil and Cervarix; which was the second cancer preventing vaccine, and the first vaccine designed to prevent a cancer. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.".